article thumbnail

Sesame Allergies Cause FDA to List Sesame as the 9th Major Allergen

XTalks

The US Food and Drug Administration (FDA) has added sesame to its list of major allergens, making it easier for people with sesame allergies to safely consume packaged food without fear of an allergic reaction. Related: Top 3 Allergy Friendly Food Brands. percent of children and adults in the US are allergic to sesame.

article thumbnail

Coronavirus vaccine may have allergy warning in US, says expert

pharmaphorum

Moncef Slaoui, co-head of the US government’s Operation Warp Speed COVID-19 vaccine programme, made the comments after the UK drugs regulator advised those with severe allergies to avoid the vaccine. The post Coronavirus vaccine may have allergy warning in US, says expert appeared first on.

Allergies 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves IND application for peanut allergy drug candidate

Outsourcing Pharma

The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.

Allergies 105
article thumbnail

EU bans cough syrup chemical over severe allergies

Medical Xpress

Cough medicines containing the chemical pholcodine should be banned due to the risk of potentially deadly allergic reactions in people under general anaesthetic, the European Union's drug regulator said Friday.

article thumbnail

COVID-19 vaccines and allergies: Updated advice needs to reach a wider audience, says BMJ

BioPharma Reporter

At the end of December, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) updated its advice on the Pfizer/BioNTech vaccine: saying that those with unrelated allergies could receive it. But this announcement did not receive as much coverage as the MHRAâs earlier pause on vaccination in people with allergies.

article thumbnail

Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment

The Pharma Data

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

article thumbnail

DBV craters on FDA’s peanut allergy immunotherapy rejection

pharmaphorum

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. The rationale behind Viaskin Peanut is to expose people with peanut allergy to small, rising amounts of peanut protein – which acts as an allergen – to encourage the immune system to develop tolerance over time.